This is alist of investigational narcolepsy and hypersomnia drugs, ordrugs that are currently under development for clinical use for the treatment ofnarcolepsy and/orhypersomnia (e.g.,excessive daytime sleepiness,idiopathic hypersomnia) but are not yet approved. Many of them may also be referred to as investigationalwakefulness-promoting agents (WPAs).

Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action – Indication [Reference]".

This list was last comprehensively updated in September 2025. It is likely to become outdated with time.

• Oveporexton (TAK-861) – orexin OX₂ receptor agonist – narcolepsy[1]
• Reboxetine (AXS-12) – norepinephrine reuptake inhibitor (NRI) – narcolepsy[2]
• Sodium oxybate (FT-218; Lumryz; ON-SXB) – GABA_B receptor agonist and GHB receptor agonist – idiopathic hypersomnia[3]

• Alixorexton (ALKS-2680) – orexin OX₂ receptor agonist – narcolepsy, idiopathic hypersomnia[4]
• Firazorexton (TAK-994) – orexin OX₂ receptor agonist – narcolepsy[5]
• Flecainide/modafinil (THN-102) – combination offlecainide (sodium channel blocker) andmodafinil (atypical dopamine reuptake inhibitor) – narcolepsy[6]
• Mazindol controlled release (NLS-0; NLS-1; NLS-10; NLS-13; NLS-2; Nolazol; Quilience) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – narcolepsy, idiopathic hypersomnia[7]
• ORX-750 – orexin OX₂ receptor agonist – narcolepsy, idiopathic hypersomnia[8]
• Pentylenetetrazole (BTD-001; pentetrazol; PTZ) – GABA_A receptor antagonist – narcolepsy, idiopathic hypersomnia[9]
• Samelisant (SUVN-G3031) – histamine H₃ receptor antagonist – narcolepsy[10]
• Serdexmethylphenidate (KP-484; KP-1077; KP-879) – norepinephrine–dopamine reuptake inhibitor (NDRI) – idiopathic hypersomnia[11]
• TAK-360 – orexin OX₂ receptor agonist – narcolepsy, idiopathic hypersomnia[12]
• TRN-257 – undefined mechanism of action – narcolepsy[13]

• Serdexmethylphenidate (KP-484; KP-1077; KP-879) – norepinephrine–dopamine reuptake inhibitor (NDRI) – narcolepsy[14]

• Danavorexton (TAK-925) – orexin OX₂ receptor agonist – narcolepsy[15]
• E-2086 – orexin OX₂ receptor agonist – narcolepsy[16]
• Lu-AH69593 – undefined mechanism of action – narcolepsy[17]
• MK-6552 – undefined mechanism of action – narcolepsy[18]
• Sodium oxybate once-nightly – GABA_B receptor agonist and GHB receptor agonist – narcolepsy[19]
• Valiloxybate (XW-10172) – GABA_B receptor agonist and GHB receptor agonist – narcolepsy[20]

• AEX-2 – orexin OX₁ and OX₂ receptor agonist – narcolepsy[21]
• HBS-102 (CSTI-100) – melanin-concentrating hormone receptor 1 (MCHR1) antagonist – narcolepsy[22][23]
• Methylphenidate transdermal (Defent) – norepinephrine–dopamine reuptake inhibitor (NDRI) – narcolepsy[24]
• NLS-11 – undefined mechanism of action – Kleine–Levin syndrome[25]
• ORX-142 – orexin OX₂ receptor agonist[26]

• AEX-19 – orexin OX₁ and OX₂ receptor agonist – narcolepsy, idiopathic hypersomnia[27]
• SPN-446 – undefined mechanism of action – narcolepsy[28]

• Armesocarb (MLR-1019; (R)-mesocarb) – atypical dopamine reuptake inhibitor (DRI) – sleep disorders[29]
• Danavorexton (TAK-925) – orexin OX₂ receptor agonist – idiopathic hypersomnia[30]
• Flecainide/modafinil (THN-102) – combination offlecainide (sodium channel blocker) andmodafinil (atypical dopamine reuptake inhibitor (DRI)) – hypersomnia[31]
• Flmodafinil (CRL-40,940; NLS-14; NLS-4; JBG01-41; bisfluoromodafinil; lauflumide) – atypical dopamine reuptake inhibitor (DRI) – idiopathic hypersomnia[32]
• Golexanolone (GR-3027) – GABA_A receptor negative allosteric modulator and neurosteroid – idiopathic hypersomnia[33]
• GSK-189254 (GSK-189254A) – histamine H₃ receptor antagonist – narcolepsy[34]
• JZP-386 (C-10323; deuterated sodium oxybate; deuterated GHB) – GABA_B receptor agonist and GHB receptor agonist – narcolepsy[35][36]
• Oveporexton (TAK-861) – orexin OX₂ receptor agonist – idiopathic hypersomnia[37]
• Research programme: neurological diseases therapies - Inexia/Nxera Pharma – orexin OX₁ and OX₂ receptor agonists – narcolepsy[38]
• Research programme: small molecule therapeutics - Orexia/X-Chem – orexin OX₂ receptor agonists[39]
• SLS-010 – histamine H₃ receptor antagonist – narcolepsy[40]
• Sodium oxybate controlled release (GHB) – GABA_B receptor agonist and GHB receptor agonist – narcolepsy[41]
• Solriamfetol (YKP-10A; YKP10A; R–228060) – undefined mechanism of action – narcolepsy[42]
• Valiloxibic acid (XWL-008) – undefined mechanism of action – narcolepsy[43]

• ABT-652 – histamine H₃ receptor modulator – sleep disorders[44]
• Bavisant (BEN-2001; JNJ-1074; JNJ-31001074) – histamine H₃ receptor antagonist – narcolepsy[45]
• Cipralisant (GT-2331; Perceptin) – histamine H₃ receptor antagonist – sleep disorders[46]
• Enerisant (TS-091; TS-0911; TS091) – histamine H₃ receptor antagonist – narcolepsy and hypersomnia[47]
• Flmodafinil (CRL-40,940; NLS-14; NLS-4; JBG01-41; bisfluoromodafinil; lauflumide) – atypical dopamine reuptake inhibitor (DRI) – narcolepsy[48]
• JNJ-17216498 – histamine H₃ receptor antagonist – narcolepsy[49]
• Lisdexamfetamine (LDX; Elvanse; NRP-104; S-877489; SHP-489; SPD-489; Tyvense; Venvanse; Vyvanse) – norepinephrine–dopamine releasing agent (NDRA) – sleep disorders[50]
• LML-134 (LML134) – histamine H₃ receptor antagonist – sleep disorders[51]
• Phacetoperane (NLS-3) – norepinephrine–dopamine reuptake inhibitor (NDRI) – narcolepsy[52]^[1]
• Research programme: sleep disorder therapeutics - Servier (S-41150) – histamine H₃ receptor antagonist – sleep disorders[53]
• SAR-152954 (SAR152954) – histamine H₃ receptor antagonist – sleep disorders[54]
• Ulotaront (SEP-363856; SEP-856) – trace amine-associated receptor 1 (TAAR1) agonist and serotonin 5-HT_1A and 5-HT_1D receptor partial agonist – narcolepsy[55]

• Mevidalen (LY-3154207; D1 PAM) – dopamine D₁ receptor positive allosteric modulator[56]^[2][3]

• Armodafinil (CEP-10953; Nuvigil; (R)-modafinil) – atypical dopamine reuptake inhibitor (DRI) – hypersomnia[57]
• Modafinil (AFT-801; Alertec; Attenace; CN-801; CRL-40476; Modasamil; Modasonil; Modavigil; Modiodal; Provigil; Sparlon; Vigil) – atypical dopamine reuptake inhibitor (DRI) – narcolepsy, hypersomnia[58]
• Solriamfetol (ADX-N05; ARL-N05; JZP-110; SKL-N05; Sunosi) – atypical norepinephrine–dopamine reuptake inhibitor (NDRI) and trace amine-associated receptor 1 (TAAR1) agonist – hypersomnia[59]

• Calcium/magnesium/potassium/sodium oxybates (GHB; JZP-258; Xywav; oxybate mixed salt solution; lower-sodium oxybate) – GABA_B receptor agonist and GHB receptor agonist – narcolepsy and idiopathic hypersomnia[60]
• Sodium oxybate (GHB; JZP-6; KEY-10; Xyrem) – GABA_B receptor agonist and GHB receptor agonist – narcolepsy[61]
• Sodium oxybate (GHB; FT-218; Lumryz; ON-SXB) – GABA_B receptor agonist and GHB receptor agonist – narcolepsy[62]

• Pitolisant (BF-2.649; BF-2649; HBS-201; Ozawade; tiprolisant; Wakix) – histamine H₃ receptor antagonist – narcolepsy, hypersomnia[63]

• Adrafinil (Olmifon; CRL-40028;N-hydroxymodafinil) – atypical dopamine reuptake inhibitor (DRI) (modafinil prodrug) – hypersomnia

• Adenosine receptor antagonists (e.g.,caffeine)^[4][5][6]
• Norepinephrine releasing agents (NRAs) (e.g.,ephedrine,selegiline (via metabolites))^[4][6]
• Norepinephrine reuptake inhibitors (NRIs) (e.g.,atomoxetine,reboxetine,viloxazine)^[7][8]
• Norepinephrine–dopamine reuptake inhibitors (NDRIs) (e.g.,bupropion,nomifensine,amineptine)^[4][5][9]
• Serotonin–norepinephrine–dopamine reuptake inhibitors (SNDRIs) (e.g.,mazindol)^[4][5]
• Stimulants (norepinephrine–dopamine releasing agents and/or reuptake inhibitors (NDRAs/NDRIs)) (e.g.,amphetamine,methamphetamine,lisdexamfetamine,methylphenidate,pemoline)^{[10][11][5][8]}

• List of investigational drugs
• List of investigational insomnia drugs
• List of investigational chronobiotics
• Wakefulness-promoting agent
• Stimulant

• AdisInsight - Springer

• Drug-related lists
• Experimental drugs

• Articles with short description
• Short description is different from Wikidata
• Dynamic lists